NCT03649750已完成1 期
A Phase I, Open-label, Single-dose, Randomized, 2-way Cross-over Study Designed to Examine the Relative Bioavailability of Guaifenesin When a Mucinex Extended Release 600 mg Bi-layer Tablet is Taken Under Fasted Compared to Fed Conditions in Normal Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 主要终点
- Maximum Observed Plasma Concentration (Cmax) of Guaifenesin
研究概览
简要总结
Determine and compare the plasma concentrations of Mucinex® Extended Release (ER) 600 mg bi-layer tablet in normal healthy volunteers in fed and fasting conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Informed consent was obtained (i.e. be informed of the nature of the study and given written consent prior to any study procedure). Able to read, understand, and sign the informed consent, after the nature of the study had been explained.
- •Age: 18 to 55 years of age, inclusive.
- •Sex: male or female.
- •Status: Healthy subjects.
- •BMI: ≥18.0 and ≤28.0 kg/m
- •No clinically significant findings in vital signs measurements at screening.
- •No clinically significant abnormal laboratory values at screening.
- •No clinically significant findings from a 12-lead electrocardiogram (ECG) at screening.
- •Had no significant diseases or clinically relevant medical condition in the opinion of the Investigator
- •Males who participated in this study were willing to:
- •remain abstinent [not engage in sexual intercourse] from the start of drug administration until 90 days after the end of the study or
- •used (or their partner used, as applicable) two effective methods of birth control [condom, diaphragm, cervical cap, vaginal sponge, spermicide, IUD, tubal ligation, vasectomy, or hormonal contraceptives] from the start of drug administration until 90 days after the end of the study.
- •Females who participated in this study were:
- •unable to have children (e.g., post-menopausal, hysterectomy);
- •willing to remain abstinent [not engage in sexual intercourse] from 21 days prior to drug administration until 30 days after the end of the study; or
- •willing to use two effective methods of birth control [condom, diaphragm, cervical cap, vaginal sponge, spermicide, non-hormonal Intrauterine Device (IUD) (in place for 3 months), tubal ligation, partner has vasectomy, hormonal contraceptives for 3 months prior to drug administration] from 30 days prior to drug administration until 30 days after the end of the study.
- •Had no clinically significant findings from a physical examination.
排除标准
- •Employee of Pharma Medica Research Inc. (PMRI) or Reckitt Benckiser.
- •Partner or first-degree relative of any Investigator at PMRI.
- •Known history or presence of any clinically significant medical condition.
- •Known or suspected carcinoma.
- •Presence of hepatic or renal dysfunction.
- •Presence of clinically significant gastrointestinal disease or history of malabsorption within the year preceding the study.
- •Known history or presence of galactose or fructose intolerance, sucrase-isomaltase insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose malabsorption syndrome.
- •Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
- •History of drug or alcohol or medicinal product addiction requiring treatment within the two years preceding the study or excessive alcohol consumption (more than 10 units per week)
- •Note: one unit is defined as 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of spirits.
- •Positive test result for serum Human Chorionic Gonadotropin (hCG) consistent with pregnancy (females only), HIV, Hepatitis B surface antigen or Hepatitis C antibody.
- •Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines, cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone and benzodiazepines) or urine cotinine.
- •Difficulty fasting or consuming standard meals.
- •Females who were lactating.
- •Did not tolerate venipuncture.
- •Use of tobacco or nicotine-containing products within 12 months prior to drug administration.
- •On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
- •Donation or loss of whole blood (including clinical trials):
- •≥50 ml and ≤499 ml within 30 days prior to drug administration
- •≥500 ml within 56 days prior to drug administration
- •Females who had started taking hormonal contraceptives or had changed their method or brand of hormonal birth control within 3 months prior to drug administration.
- •Had a tattoo or body piercing within 30 days prior to drug administration.
- •Use of drugs of the monoamine oxidase inhibitor (MAOI) class within 30 days prior to drug administration.
- •Known history or presence of hypersensitivity, intolerance or idiosyncratic reaction to guaifenesin or any other drug substances with similar activity.
- •Previously enrolled in this study.
- •Participated in another clinical trial or received an investigational product within 30 days prior to drug administration.
- •Unable in the opinion of the Investigator to comply fully with the study requirements.
研究组 & 干预措施
Treatment A: Mucinex® 600 mg (fast)
Experimental
Mucinex® 600 mg ER bi-layer tablet by mouth after 10 hours fasting and subject will fast at least 4 hours post-dose
干预措施: Mucinex® (Drug)
Treatment B: Mucinex® 600 mg (fed)
Experimental
Mucinex® 600 mg ER bi-layer tablet by mouth in fed condition. After an overnight fast of at least 10 hours, subjects will consume a high fat, high calorie breakfast starting 30 minutes prior to drug administration
干预措施: Mucinex® (Drug)
结局指标
主要结局
Maximum Observed Plasma Concentration (Cmax) of Guaifenesin
时间窗: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)
Maximum measured analyte concentration over the sampling period.
Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Plasma Concentration (AUCt) of Guaifenesin
时间窗: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2)
The area under the analyte concentration versus time curve, from time zero (0) to the time of the last measurable analyte concentration (t), as calculated by the linear trapezoidal method.
次要结局
- Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin(0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2))
- Relative Bioavailability (RF) of Guaifenesin(0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2))
- Terminal Elimination Rate Constant (Kel) of Guaifenesin(0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2))
- Terminal Elimination Half-life (T½) of Guaifenesin(0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2))
- Number of Adverse Events(AEs) Experienced by Participants(Up to period 2 (8.3 days/200 hours))
- Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin(0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20, and 24 hours (Period 1 and 2))
研究者
相似试验
已完成
1 期
Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy VolunteersHealthy SubjectsNCT03644108Reckitt Benckiser Inc.30
已完成
1 期
Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4hHealthy SubjectsNCT03642262Reckitt Benckiser Inc.30
已完成
1 期
Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release TabletHealthy SubjectsNCT03633487Reckitt Benckiser LLC24
已完成
1 期
Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy VolunteersHealthy SubjectsNCT03644095Reckitt Benckiser Inc.30
已完成
1 期
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid TumorsNeoplasms MalignantNCT04047290Akesobio Australia Pty Ltd80